There are no products listed under this category.
CellMosaic offers a complete antibody-drug conjugate (ADC) discovery and development program for pharmaceutical and biotech companies based on classical linkers and our advanced conjugation processes. Each antibody is unique, as the particular linker and chemistry that works for one ADC may not apply to others. CellMosaic has the in-house capability and expertise to devise and execute appropriate strategies to fit your ADC development plan.
The services we provide include:
Depending on the needs of a customer’s project, the typical turn-around time for synthesizing an ADC for initial proof-of-concept is 4-6 weeks. Please contact us to discuss your project.
In the event an ADC cannot be made using classical linkers or the effectiveness of the ADCs are compromised by the number of toxins loaded onto the antibody, AqueaTether ™ Therapeutics, a separate division of CellMosaic, has developed novel super-hydrophilic and high-loading AqueaTether ™ linkers specifically to solve these problems. To explore this opportunity and learn more about AqueaTether ™ platform technologies, please visit our website at aqttherapeutics.com
There are no products listed under this category.